免疫检查点抑制剂联合血管内皮生长因子抑制剂一线治疗晚期不可切除肝细胞癌的临床疗效  

Clinical efficacy of immune checkpoint inhibitor plus vascular endothelial growth factor inhibitor in the first-line treatment of advanced unresectable hepatocellular carcinoma

作　　者：邱虎[1] 柯少波[1] 蔡高科 陈永顺[1] Qiu Hu;Ke Shaobo;Cai Gaoke;Chen Yongshun(Department of Clinical Oncology,Renmin Hospital of Wuhan University,Wuhan 430060,China)

机构地区：[1]武汉大学人民医院肿瘤中心,武汉430060

出　　处：《中华消化外科杂志》2022年第S01期29-34,共6页Chinese Journal of Digestive Surgery

摘　　要：近10年来,晚期不可切除肝细胞癌在系统治疗上取得了快速突破性进展。单一系统治疗对肿瘤局部复发和远处转移控制不理想,联合治疗模式是绝大多数晚期肝细胞癌患者的治疗方案。肿瘤微环境的变化是目前抗肿瘤治疗的研究热点,靶向治疗、免疫治疗及放射治疗均可诱导原发性肝癌微环境发生变化。因此,联合治疗的协同作用显得尤为重要。笔者报道1例程序性死亡[蛋白]配体-1抑制剂联合血管内皮生长因子抑制剂一线治疗晚期不可切除肝细胞癌的临床疗效。其研究结果显示:依据改良实体瘤疗效评价标准评价为部分缓解,患者生存时间>20个月,无明显不良反应,生命质量高。In the past decade,rapid breakthroughs have been made in the systemic treat-ment of advanced unresectable hepatocellular carcinoma.Single systemic therapy has little effect on controlling tumor local recurrence and distant metastasis,and the combination modality therapy is the treatment for the majority of patients with advanced hepatocellular carcinoma.The change of tumor microenvironment is the research hotspot of antitumor therapy at present.Targeted therapy,immunotherapy and radiotherapy can lead to a change in the tumor microenvironment of primary hepatic carcinoma.The synergistic effect of combined therapy is particularly important.The authors report the clinical efficacy of programmed death ligand-1 inhibitor plus vascular endothelial growth factor inhibitor in the first-line treatment of a patient with advanced unresectable hepatocellular carci-noma.The results show that partial response being achieved according to the modified response evaluation criteria in solid tumors,and the survival time is more than 20 months with no obvious adverse reactions and high quality of life.

关 键 词：肝肿瘤 免疫治疗 程序性死亡[蛋白]配体-1抑制剂 血管内皮生长因子抑制剂 联合治疗 

分 类 号：R735.7[医药卫生—肿瘤]